Search

Your search keyword '"Egeland T"' showing total 528 results
Start Over Author "Egeland T" Search Limiters Academic (Peer-Reviewed) Journals
528 results on '"Egeland T"'

10. The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

Author

Remberger, Mats, Grønvold, B., Ali, M., Mattsson, J., Egeland, T., Lundin, K. U., Myhre, A., Abrahamsen, I., Heldal, D., Dybedal, I., Tjønnfjord, G. E., Gedde-Dahl, T., Fløisand, Y., Remberger, Mats, Grønvold, B., Ali, M., Mattsson, J., Egeland, T., Lundin, K. U., Myhre, A., Abrahamsen, I., Heldal, D., Dybedal, I., Tjønnfjord, G. E., Gedde-Dahl, T., and Fløisand, Y.

Abstract

The effect of CD34+ cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been performed. Our single center analysis included 189 patients with hematological malignancies who received peripheral blood stem cell (PBSC) grafts from sibling donors. Myeloablative conditioning was used in 88 cases and 101 received reduced intensity conditioning. The median CD34+ cell dose was 5.6 × 106/kg (0.6–17.0). In the multivariate analysis, a CD34 cell dose of 6–7 × 106/kg was associated with better OS and lower transplant-related mortality (TRM), while a dose of <5 × 106/kg led to increased relapse and reduced chronic GVHD (cGVHD). A high CD34 cell-dose (>6.5 × 106/kg) correlated with less acute GVHD (aGVHD) II–IV. We conclude that the CD34 cell dose has an impact on the outcome of HSCT from sibling donor PBSCs.

Published
2020
Full Text
View/download PDF

11. HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation

Author

Grønvold, B., Ali, M. M., Remberger, Mats, Mattsson, J., Egeland, T., Lundin, K. U., Myhre, A. E., Abrahamsen, I. W., Heldal, D., Dybedal, I., Tjønnfjord, G. E., Fløisand, Y., Gedde-Dahl, T., Grønvold, B., Ali, M. M., Remberger, Mats, Mattsson, J., Egeland, T., Lundin, K. U., Myhre, A. E., Abrahamsen, I. W., Heldal, D., Dybedal, I., Tjønnfjord, G. E., Fløisand, Y., and Gedde-Dahl, T.

Published
2020
Full Text
View/download PDF

21. HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation

Author

Grønvold, B., primary, Ali, M. M., additional, Remberger, M., additional, Mattsson, J., additional, Egeland, T., additional, Lundin, K. U., additional, Myhre, A. E., additional, Abrahamsen, I. W., additional, Heldal, D., additional, Dybedal, I., additional, Tjønnfjord, G. E., additional, Fløisand, Y., additional, and Gedde-Dahl, T., additional

Published
2020
Full Text
View/download PDF

23. Comment

Author

Selmer, K. K., Egeland, T., Solaas, M. H., Nakken, K. O., Kjeldsen, M. J., Friis, M. L., Brandal, K., Corey, L. A., and Undlien, D. E.

Published
2008

36. Editorial Acknowledgment

Author

Aarvak, T., Abedi-Valugerdi, M., Abrahamsen, T., Akdis, C., Akuffo, H.O., Alarcon-Riquelme, M., Andersen, P., Arstila, P., Austgulen, R., Baecker-Allan, C., Baggiolini, M., Baker, B.S., Bakke, O., Bakken, V., Barclay, A.N., Bemark, M., Benestad, H.B., Berzins, K., Bjerkvik, R., Bjørge, L., Bland, P., Bolstad, A.I., Born, W., Bowman, S., Brinchmann, J., Britton, S., Brokstad, K.A., Brunet, L.R., Bruserud, Ø., Cardona, P.J., Ceyppens, J.L., Cirino, G., Cohn, M., Cox, R.J., Cunliffe, J., Dahlgren, U., Dellacasagrande, J., Ditzel, H., Dobryszycka, E., Dyrhol-Riise, A.M., Edwards, J.C., Egeland, T., Elsayed, S., Eray, M., Erb, K.J., Esch, T., Eugen-Olsen, J., Everse, L.A., Fagerhol, M., Farstad, I., Feldmann, M., Fernandez, C., Fleck, M., Franksson, R., Freitas, A., Garred, P., Gidlund, M., Gilhus, N.E., Goldbach-Mansky, R., Gordon, J., Gordon, T., Grandien, A., Gregerson, P., Grewal, H., Hakulinen, J., Halstensen, T., Haneberg, B., Hanej, S.H.E., Hansen, T., Harley, J.B., Haukenes, G., Hengartner, H., Henz, B.M., Holen, E., Hurme, M., Husby, G., Husby, S., Hörnqvist-Hultgren, E., Haaheim, L.R., Isenberg, D., Jahnson, F., Jakobsen, H., James, J.A., Jansson, J.O., Jarva, H., Jeansson, S., Johannessen, A.C., Johansen, F.E., Julkunen, I., Kalland, K.H., Kaye, J., Kazatchkine, M., Kihlström, E., Kohler, L., Konttinen, Y., Kotenko, S., Koutzov, S., Krammer, P., Kristoffersen, E., Kunzendorf, U., Lachmann, P., Langman, R., Langner, J., Lanzavecchia, L., Lappalainen, M., Laskay, T., Lea, T., Lefvert, A.K., Lehmann, A.C., Louka, A, Lúdviksson, B.R., Mariette, X., Marion, T., Marker-Herrmann, E., Mattsson, R., McAdam, S., Mellbye, O.J., Mellgren, G., Mellgren, S.I., Mestecky, J., Michaelsen, T., Michalek, S., Miettinen, A., Moestrup, S.K., Moretta, A., Moser, M., Mountz, J., Moutsopoulos, H., Munthe, L.A., Mustafa, T., Myrmel, H., Nannemark, G., Netea, M.G., Nilsen, R., Notarangelo, L.D., Ögmundsdóttir, H., Olsson, I., Olweus, J., Osland, A., Paludan, S.R., Parsons, K.R., Patarroyo, M., Paul, W.E., Perlman, P., Pollock, J.M., Puolakkainen, M., Quale, A., Rajewsky, K., Raman, C., Reichlin, M., Renkonen, R., Rese Shadidi, K., Ricciardi-Castagnoli, P., Rickinson, A.B., Ringdén, O., Risto, R., Rodinov, D., Rosenkrands, I., Rottenberg, M., Russel, M., Rygaard, J., Rødahl, E., Röllinghof, M., Sandberg, M., Schenk, K., Seppälä, I., Shevach, E., Shortman, K., Siegrist, C.A., Sigurdardóttir, S., Silvennoinen, O., Sinigaglia, F., Sistonen, L., Skarstein, K., Skogh, T., Smith, E., Spurkland, A., Stendahl, O., Sugden, B., Suri-Payer, E., Svennerholm, A.M., Szodoray, P., Theofilopoulos, A., Thorley-Lawson, D.A., Timonen, T., Trowsdale, J., Tuomo, T., Ulmer, A.J., Ulvestad, E., Ulvik, R., Vaerman, J.P., van, der Merwe J.P., van Eden, W., Vedeler, C., Vintermyr, O.K., Vyse, J., Wahlgren, M., Wahren-Herlenius, M., Walsh, L.J., Weetman, A.P., Westermark, P., Wiker, H., Yang, J., Yewdell, J.W., Youinou, P., and Zouali, M.

Published
2002

43. DNA Commission of the International Society for Forensic Genetics: Recommendations on the validation of software programs performing biostatistical calculations for forensic genetics applications

Author

Coble, M. D., Buckleton, J., Butler, J. M., Egeland, T., Fimmers, R., Gill, P., Gusmao, L., Guttman, B., Krawczak, M., Morling, N., Parson, W., Pinto, N., Schneider, P. M., Sherry, S. T., Willuweit, S., Prinz, M., Coble, M. D., Buckleton, J., Butler, J. M., Egeland, T., Fimmers, R., Gill, P., Gusmao, L., Guttman, B., Krawczak, M., Morling, N., Parson, W., Pinto, N., Schneider, P. M., Sherry, S. T., Willuweit, S., and Prinz, M.

Abstract

The use of biostatistical software programs to assist in data interpretation and calculate likelihood ratios is essential to forensic geneticists and part of the daily case work flow for both kinship and DNA identification laboratories. Previous recommendations issued by the DNA Commission of the International Society for Forensic Genetics (ISFG) covered the application of bio-statistical evaluations for STR typing results in identification and kinship cases, and this is now being expanded to provide best practices regarding validation and verification of the software required for these calculations. With larger multiplexes, more complex mixtures, and increasing requests for extended family testing, laboratories are relying more than ever on specific software solutions and sufficient validation, training and extensive documentation are of upmost importance. Here, we present recommendations for the minimum requirements to validate bio-statistical software to be used in forensic genetics. We distinguish between developmental validation and the responsibilities of the software developer or provider, and the internal validation studies to be performed by the end user. Recommendations for the software provider address, for example, the documentation of the underlying models used by the software, validation data expectations, version control, implementation and training support, as well as continuity and user notifications. For the internal validations the recommendations include: creating a validation plan, requirements for the range of samples to be tested, Standard Operating Procedure development, and internal laboratory training and education. To ensure that all laboratories have access to a wide range of samples for validation and training purposes the ISFG DNA commission encourages collaborative studies and public repositories of STR typing results. Published by Elsevier Ireland Ltd.

Published
2016

44. DNA Commission of the International Society for Forensic Genetics:Recommendations on the validation of software programs performing biostatistical calculations for forensic genetics applications

Author

Coble, M. D., Buckleton, J., Butler, J M, Egeland, T., Fimmers, R., Gill, P., Gusmão, L., Guttman, B., Krawczak, M., Morling, N., Parson, W., Pinto, N., Schneider, P. M., Sherry, S. T., Willuweit, S., Prinz, M., Coble, M. D., Buckleton, J., Butler, J M, Egeland, T., Fimmers, R., Gill, P., Gusmão, L., Guttman, B., Krawczak, M., Morling, N., Parson, W., Pinto, N., Schneider, P. M., Sherry, S. T., Willuweit, S., and Prinz, M.

Abstract

The use of biostatistical software programs to assist in data interpretation and calculate likelihood ratios is essential to forensic geneticists and part of the daily case work flow for both kinship and DNA identification laboratories. Previous recommendations issued by the DNA Commission of the International Society for Forensic Genetics (ISFG) covered the application of bio-statistical evaluations for STR typing results in identification and kinship cases, and this is now being expanded to provide best practices regarding validation and verification of the software required for these calculations. With larger multiplexes, more complex mixtures, and increasing requests for extended family testing, laboratories are relying more than ever on specific software solutions and sufficient validation, training and extensive documentation are of upmost importance. Here, we present recommendations for the minimum requirements to validate bio-statistical software to be used in forensic genetics. We distinguish between developmental validation and the responsibilities of the software developer or provider, and the internal validation studies to be performed by the end user. Recommendations for the software provider address, for example, the documentation of the underlying models used by the software, validation data expectations, version control, implementation and training support, as well as continuity and user notifications. For the internal validations the recommendations include: creating a validation plan, requirements for the range of samples to be tested, Standard Operating Procedure development, and internal laboratory training and education. To ensure that all laboratories have access to a wide range of samples for validation and training purposes the ISFG DNA commission encourages collaborative studies and public repositories of STR typing results.

Published
2016

45. AMINOETHYL-ISOTHIOUREA INHIBITS THE INCREASE IN PLASMA ENDOTHELIN-1 CAUSED BY SEROGROUP A STREPTOCOCCI AND PROLONGS SURVIVAL IN RAT PERITONEAL SEPSIS

Author

G. Lermark, E. A. Hoiby, T. Saetre, Torstein Lyberg, T. Aspelin, Aud Svindland, and Egeland T

Subjects
Endothelin Receptor Antagonists, Male, Time Factors, Streptococcus pyogenes, medicine.drug_class, Nitric Oxide Synthase Type II, Blood Pressure, Pharmacology, Biology, Critical Care and Intensive Care Medicine, Nitric oxide, Rats, Sprague-Dawley, chemistry.chemical_compound, Streptococcal Infections, Intensive care, medicine, Animals, Enzyme Inhibitors, Antihypertensive Agents, chemistry.chemical_classification, Sulfonamides, Reactive oxygen species, Endothelin-1, Thiourea, Bosentan, Receptor, Endothelin A, Receptor antagonist, Shock, Septic, Endothelin 1, Rats, Survival Rate, Nitric oxide synthase, chemistry, Biochemistry, Mechanism of action, Emergency Medicine, biology.protein, Nitric Oxide Synthase, medicine.symptom, medicine.drug
Abstract

To elucidate the possible roles of nitric oxide (NO), endothelin-1 (ET-1), and reactive oxygen species (ROS) in the pathophysiology of serogroup A streptococcal (GAS) peritoneal sepsis, we investigated the effects of aminoethylisothiourea (AE-ITU), an inducible NO synthase (iNOS) inhibitor, and a ROS scavenger, and the ET-1 receptor antagonist bosentan. In rats, live GAS inocula, 3 x 10(8) and 1 x 10(9) cfu/kg, entailed a 24-h mortality of 10% and 90%, respectively. GAS caused increases in tissue iNOS activity (9 h), in serum nitrite/nitrate (9-24 h), and in intracellular leukocyte ROS levels (3-6 h). These changes were all prevented by the pre-treatment with AE-ITU. A novel finding was that AE-ITU also prevented the GAS-induced marked increase in plasma ET-1 at 6 h. Short-term (7-h) survival was improved by both AE-ITU and by bosentan. The mechanism(s) for the beneficial effects of AE-ITU may possibly be a combined mode of action; iNOS inhibition, ROS scavenging, and inhibition of the increase in plasma ET-1 caused by GAS.

Published
2001

46. Aminoethyl-isothiourea, a nitric oxide synthase inhibitor and oxygen radical scavenger, improves survival and counteracts hemodynamic deterioration in a porcine model of streptococcal shock

Author

G. Lermark, E. A. Hoiby, Torstein Lyberg, Egeland T, T. Saetre, and T. Aspelin

Subjects
Male, Streptococcus pyogenes, Swine, Radical, Pharmacology, Nitric Oxide, Critical Care and Intensive Care Medicine, medicine.disease_cause, Nitric oxide, Sepsis, Random Allocation, chemistry.chemical_compound, Streptococcal Infections, Animals, Medicine, biology, business.industry, Hemodynamics, Thiourea, Oxygen transport, medicine.disease, Shock, Septic, Survival Rate, Nitric oxide synthase, Disease Models, Animal, Biochemistry, chemistry, Enzyme inhibitor, Shock (circulatory), biology.protein, Female, medicine.symptom, business, Isothiuronium
Abstract

To test the effect of a continuous infusion of the nitric oxide (NO) synthase (S) inhibitor aminoethyl-isothiourea (AE-ITU) on survival time, hemodynamics, and oxygen transport in a porcine model of live group A streptococcal (GAS) sepsis. Furthermore, to examine the role of endothelin-1, histamine, and reactive oxygen species (ROS) in streptococcal shock.Prospective, randomized trial.Laboratory at a university hospital.Twenty-eight pigs with an average weight of 25 kg.Sixteen animals received a continuous infusion of live Streptococcus pyogenes 1.3 x 10(10) colony forming units/hr: eight received fluids only, and the other eight received an intravenous infusion of AE-ITU 10 mg/kg/hr starting 30 mins before the GAS challenge. Six control pigs received AE-ITU 10 mg/kg/hr iv for 5 hrs. Another six animals received half the dose of GAS over 5 hrs.GAS infusion caused a rapid increase in pulmonary, hepatic, and systemic vascular resistance, followed by hypotension with a 90% lethality at 4 hrs. Treatment with AE-ITU increased 4-hr survival in septic animals from 1/8 to 8/8 and 5-hr survival from 0/8 to 5/8, prevented hypotension, and increased urine output. AE-ITU attenuated the decrease in cardiac output, liver blood flow, and oxygen delivery, and hepatic arterial blood flow as a fraction of cardiac output increased (all p.05). Plasma nitrate/nitrite levels decreased in all animals. Inducible NOS and endothelial constitutive NOS activities in liver, gut, and lung were not increased during sepsis, nor were they decreased after AE-ITU. Plasma levels of endothelin-1 and methylhistamine increased in all septic animals and were not modified by AE-ITU. AE-ITU prevented the increase in monocyte ROS production caused by GAS. In control animals, AE-ITU caused an increase in mean arterial pressure, liver blood flow, and oxygen delivery.In this model of porcine GAS-induced septic shock, which was not associated with enhanced NO production, infusion of the NOS inhibitor AE-ITU prolonged survival, prevented hypotension, and improved cardiac contractility, organ perfusion, and tissue oxygenation. These beneficial effects of AE-ITU might be a result of the combined effect of ROS scavenging and modulation of local NO production, thus improving the balance of vasodilator and vasoconstrictor forces and reducing oxidative stress.

Published
2000

50. Eular workshop on Rheumatology Research: Noordwijkerhout February 1982

Author

Bjelle, A., Cedergren, B., Wählby, L., Boerbooms, A. P. Th., Geerdink, P. J., van de Putte, L. B. A., Ouweland, F. A. M., Buchanan, R. R. C., Morgan, A., Staines, N. A., Venables, P. J. W., Maini, R. N., Bucknall, R. C., Bacon, P. A., Jones, J. Verrier, Leirisalo, M., Laitinen, O., Bühring, M., Rosak, C., Stöckle, W., Magnet, W., Catogio, L. J., Bernstein, R. M., Black, C. M., Hughes, G. R. V., Maddison, P. J., Charles P. J., Venables P. J. W., Tung Yi., Buchanan R. C., Maini R. N., Deicher, H., Weißbarth, E., Zeller, J., Baruth, B., Delbarre, F., de Gery, A., Kahan, A., de Vries, E., van der Veen, C. J. P., van der Weij, J. P., Klein, F., de Bruijn, A. M., Cats, A., Dreher, R., Coworkers, Duclos, M., Peter, H., Zeidler, H., Rieber, P., Pichler, J., Limany, W., Dunn, N., Hurst, N. P., Denholm, E., Nuki, G., Ebringer, A., Hayes, J., Cowling, P., Ebringer, R., Egeland, T., Forre, Ø., Festen, J. J. M., Kuipers, F. H., Schaars, A. H., Førre, Ø., Waalen, K., Mellbye, O. J., Froebel, K., Lewis, D., Sturrock, R. D., Goldschmeding, R., Limburg, P. C., Pastoor, G. W., Houtman, P. M., Kallenberg, C. G. M., Halberg, P., Lorenzen, I., Bennedsen, J., Rhodes, J. M., Hall, N. D., Eales, L. -J., Blake, D. R., Hunneyball, I. M., Helmke, K., Boeder, T., Teuber, J., Hermanns, P., Veys, E. M., Verbruggen, G., Horsfall, A. C., Mumford, P. A., Schrieber, L., Huber, O., Kluin-Nelemans, H., Vernooy, J., Meyling, F. Gmelig, Derksen, R., Kater, L., Hurst N. P., Nuki G., Husby, G., Gran, J. T., Thorsby, E., Johnson, G. D., Bainbridge, D. R., Holborow, E. J., Bubel, M., Goddard, D. H., Jonsson, J., Norberg, R., Schilling, W., Kalden, R., Leitner, O., Manger, B., Beck, A., Koch, B., de Jong, M. C. J. M., Walstra, T., van der Meulen, J., Kávai, M., Bányai, A., Zsindely, A., Sonkoly, I., Szegedi, Gy., Klareskog, L., Forsum, U., Scheynius, A., Kabelitz, D., Wigzell, H., Koivuranta, P., Repo, H., Kiistala, U., Österman, P., Konttinen, Y., Friman, C., Tolvanen, E., Johansson, E., Konttinen, Y. T., Reitamo, S., Seppä, A., Malmström, M., Lindström, F., Hellquist, H., Olofsson, J., Maddison, PJ., Black, CM., Jayson, MIV, Batchelor, J. R., Walsh, Kl., Bernstein, RM, Catoggio, LJ., Holland, CD., Hughes, GRV, Mbuyi, J. M., Dequeker, J., Förre Ö, Johnsen, W., Meijer, C. J. L. M., de Graaf-Reitsma, C., Lafeber, G. J. M., Meyer, O., Borda-Oriarte, O., Haïm, T., Ryckewaert, A., Mielants, H., Van Steenkiste, M., De Langhe, J., Buchanan, R. C., Moutsopoulos, M., Hooks, J., Mumford, P., Patel, V., Panayi, G. S., Piatier-Tonneau, D., Mach, P. S., Plater-Zyberk, C., Clarke, M., Raeman, F., De Cock, W., Leempoels, J., De Cree, J., Verhaegen, H., Ranki, A., Paavonen, T., Kankaanpää, U., Nilsson, E., Biberfeld, G., Room, G., Saal, J. G., Frank, F., Rauteenstrauch, H., Hadam, M., Fritz, P., Laschner, W., Scheper, R. J., von Blomberg-van der Flier, B. M. E., Boerrigter, G. H., van Bruynzeel, D., van Dinther-Janssen, A. C. H. M., Simon, K. H., Schmidt, R. E., Erhardt, C. C., Melsom, R. D., McCarthy, J., Smeenk, R., Van der Lelij, G., Aarden, L., Staite, N. D., Stierle, H. E., Brown, K. A., Perry, J. D., Swaak, A. J. G., Groenwold, J., Smeenk, R. J. T., Toenes, G. H., Edel, H. H., Eggert, K., Held, E., Hübner, F. K., Schattenkirchner, M., Wegelius, O., Tron, F., Jacob, L., Bach, J. F., Lens, J. W., van den Berg, W. B., van Rijswijk, M. H., van Leeuwen, M. A., van der Giessen, M., The, T. H., van Venrooij, W. J., van Eekelen, C. A. G., Habets, W. J. A., Salden, M. H. L., de Rooij, D. J., Van Wanghe, P., Hermanns, Ph., Van Bruwaene, Ph., De Brabanter, G., De Landsheere, D., Immesoete, C., Walravens, M. J. F., Stevens, E., Warnatz, H., Lemm, G., Wiik, A., Petersen, J., Permin, H., Wollheim, F. A., Carlsson, J., Forsgren, A., Pettersson, H., Youinou, P., Miossec, P., and Le Goff, P.

Published
1982
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results